Compounds > xanthenes
Page last updated: 2024-08-18

xanthenes and Substance Withdrawal Syndrome

xanthenes has been researched along with Substance Withdrawal Syndrome in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chaki, S; Iijima, M; Koike, H1
Carson, JR; Codd, EE; Colburn, RW; Dax, SL; Flores, CM; Gallantine, EL; Meert, TF; Molino, L; Pullan, S; Razler, CM; Stone, DJ; Van Besien, CR; Wade, PR; Zhang, SP1
Hsu, MA; Rasmussen, K; Vandergriff, J1
Liechti, ME; Markou, A1
Ferholt, JB; Stone, WN1

Other Studies

5 other study(ies) available for xanthenes and Substance Withdrawal Syndrome

ArticleYear
Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine.
    Behavioural brain research, 2013, Jun-01, Volume: 246

    Topics: Amino Acids; Analysis of Variance; Animals; Central Nervous System Stimulants; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Interactions; Excitatory Amino Acid Antagonists; Immobility Response, Tonic; Male; Methamphetamine; Motor Activity; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Swimming; Xanthenes

2013
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic toler
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 329, Issue:1

    Topics: Alfentanil; Analgesics, Opioid; Animals; Azabicyclo Compounds; Cricetinae; Drug Tolerance; Gastrointestinal Motility; Guanosine 5'-O-(3-Thiotriphosphate); Hot Temperature; Hyperalgesia; Irritants; Male; Mice; Pain Measurement; Rats; Rats, Wistar; Receptors, Opioid, delta; Respiratory Insufficiency; Seizures; Self Administration; Stomach Ulcer; Substance Withdrawal Syndrome; Substance-Related Disorders; Xanthenes; Zymosan

2009
The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons.
    Neuropharmacology, 2004, Volume: 46, Issue:5

    Topics: Action Potentials; Amino Acids; Animals; Excitatory Amino Acid Antagonists; Locus Coeruleus; Male; Morphine Dependence; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Substance Withdrawal Syndrome; Xanthenes

2004
Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    European journal of pharmacology, 2007, Jan-12, Volume: 554, Issue:2-3

    Topics: Amino Acids; Animals; Dose-Response Relationship, Drug; Drug Interactions; Eating; Excitatory Amino Acid Antagonists; Ganglionic Stimulants; Infusions, Intravenous; Injections, Intraperitoneal; Male; Nicotine; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Reinforcement Schedule; Reward; Self Administration; Substance Withdrawal Syndrome; Time Factors; Xanthenes

2007
Severe delirium after abrupt withdrawal of thiothixene in a chronic schizophrenic inpatient.
    The Journal of nervous and mental disease, 1970, Volume: 150, Issue:5

    Topics: Chronic Disease; Delirium; Hospitalization; Humans; Male; Middle Aged; Schizophrenia; Substance Withdrawal Syndrome; Xanthenes

1970